Working… Menu
Trial record 9 of 24 for:    Ad26.ZEBOV

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02564523
Recruitment Status : Completed
First Posted : September 30, 2015
Last Update Posted : February 17, 2020
EBOVAC2 Consortium
Institut National de la Santé Et de la Recherche Médicale, France
Centre Muraz
Information provided by (Responsible Party):
Janssen Vaccines & Prevention B.V.

No Study Results Posted on for this Study
Recruitment Status : Completed
Actual Primary Completion Date : February 12, 2019
Actual Study Completion Date : February 12, 2019
Certification/Extension First Submitted : February 10, 2020